Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 20.
doi: 10.1007/s11030-023-10795-4. Online ahead of print.

Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer

Anushka Sharma  1 , Rahul Dubey  1 , Vikas Asati  2 , Gurkaran Singh Baweja  1 , Shankar Gupta  1 , Vivek Asati  3
Affiliations
Review

Assessment of structural and activity-related contributions of various PIM-1 kinase inhibitors in the treatment of leukemia and prostate cancer

Anushka Sharma et al. Mol Divers. .

Abstract

One of the most perilous illnesses in the world is cancer. The cancer may be associated with the mutation of different genes inside the body. The PIM kinase, also known as the serine/threonine kinase, plays a critical role in the biology of different kinds of cancer. They are widely distributed and associated with several biological processes, including cell division, proliferation, and death. Aberration of PIM-1 kinase is found in varieties of cancer. Prostate cancer and leukemia can both be effectively treated with PIM-1 kinase inhibitors. There are several potent compounds that have been explored in this review based on heterocyclic compounds for the treatment of prostate cancer and leukemia that have strong effects on the suppression of PIM-1 kinase. The present review summarizes the PIM-1 kinase pathway, their inhibitors under clinical trial, related patents, and SAR studies of several monocyclic, bicyclic, and polycyclic compounds. The study related to their molecular interactions with receptors is also included in the present manuscript. The study may be beneficial to scientists for the development of novel compounds as PIM-1 inhibitors in the treatment of prostate cancer and leukemia.

Keywords: Heterocyclic compounds; Leukemia; PIM-1 inhibitor; Prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Alizadeh AM, Shiri S, Farsinejad S (2014) Metastasis review: from bench to bedside. Tumor biology 35:8483–8523. https://doi.org/10.1007/s13277-014-2421-z - DOI - PubMed
    1. Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH et al (2020) Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open 10(11):e043828. https://doi.org/10.1136/bmjopen-2020-043828 - DOI - PubMed
    1. Kashyap MP, Sinha R, Mukhtar MS, Athar M (2022) Epigenetic regulation in the pathogenesis of non-melanoma skin cancer. Semin Cancer Biol 83:36–56. https://doi.org/10.1016/j.semcancer.2020.11.009 - DOI - PubMed
    1. Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63–89. https://doi.org/10.14740/wjon1191 - DOI - PubMed - PMC
    1. Wang L, Lu B, He M, Wang Y, Wang Z, Du L (2022) Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 10:811044. https://doi.org/10.3389/fpubh.2022.811044 - DOI - PubMed - PMC

LinkOut - more resources